hGH fragment is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-10-09. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
==== MeSH D13.444.308 – DNA ==== MeSH D13.444.308.135 – DNA adducts MeSH D13.444.308.142 – DNA, a-form MeSH D13.444.308.148 – DNA, algal MeSH D13.444.308.150 – DNA, antisense MeSH D13.444.308.150.640 – oligodeoxyribonucleotides, antisense MeSH D13.444.308.180 – DNA, archaeal MeSH D13.444.308.212 – DNA, bacterial MeSH D13.444.308.227 – DNA, c-form MeSH D13.444.308.243 – DNA, catalytic MeSH D13.444.308.283 – DNA, circular MeSH D13.444.308.283.084 – DNA, catenated MeSH D13.444.308.283.170 – DNA, chloroplast MeSH D13.444.308.283.225 – DNA, mitochondrial MeSH D13.444.308.283.225.200 – DNA, kinetoplast MeSH D13.444.308.283.250 – DNA, superhelical MeSH D13.444.308.291 – DNA, concatenated MeSH D13.444.308.295 – DNA, cruciform MeSH D13.444.308.300 – DNA, fungal MeSH D13.444.308.315 – DNA, helminth MeSH D13.444.308.324 – DNA, intergenic MeSH D13.444.308.324.230 – DNA, ribosomal spacer MeSH D13.444.308.425 – DNA, neoplasm MeSH D13.444.308.435 – DNA, plant MeSH D13.444.308.435.275 – DNA, chloroplast MeSH D13.444.308.442 – DNA, protozoan MeSH D13.444.308.442.200 – DNA, kinetoplast MeSH D13.444.308.460 – DNA, recombinant MeSH D13.444.308.475 – DNA, ribosomal MeSH D13.444.308.475.230 – DNA, ribosomal spacer MeSH D13.444.308.480 – DNA, satellite MeSH D13.444.308.497 – DNA, single-stranded MeSH D13.444.308.497.220 – DNA, complementary MeSH D13.444.308.520 – DNA transposable elements MeSH D13.444.308.568 – DNA, viral MeSH D13.444.308.574 – DNA, z-form MeSH D13.444.308.580 – isochores MeSH D13.444.308.760 – retroelements
zygonema Also zygotene stage. In meiosis, the second of five substages of prophase I, following leptonema and preceding pachynema. During zygonema, synapsis occurs, physically binding homologous chromosomes to each other, and the cell's centrosome divides into two daughter centrosomes, each containing a single centriole.
Single-walled nanotubes are likely candidates for miniaturizing electronics. The most basic building block of these systems is an electric wire, and SWNTs with diameters of an order of a nanometre can be excellent conductors. One useful application of SWNTs is in the development of the first intermolecular field-effect transistors (FET). The first intermolecular logic gate using SWCNT FETs was made in 2001. A logic gate requires both a p-FET and an n-FET. Because SWNTs are p-FETs when exposed to oxygen and n-FETs otherwise, it is possible to expose half of an SWNT to oxygen and protect the other half from it. The resulting SWNT acts as a not logic gate with both p- and n-type FETs in the same molecule. Large quantities of pure CNTs can be made into a freestanding sheet or film by surface-engineered tape-casting (SETC) fabrication technique which is a scalable method to fabricate flexible and foldable sheets with superior properties. Another reported form factor is CNT fiber (a.k.a. filament) by wet spinning. The fiber is either directly spun from the synthesis pot or spun from pre-made dissolved CNTs. Individual fibers can be turned into a yarn. Apart from its strength and flexibility, the main advantage is making an electrically conducting yarn. The electronic properties of individual CNT fibers (i.e. bundle of individual CNT) are governed by the two-dimensional structure of CNTs. The fibers were measured to have a resistivity only one order of magnitude higher than metallic conductors at 300 K (27 °C; 80 °F).
In Russia, Acting Governor of Kursk Oblast, Alexei Smirnov, claimed that drone attacks caused fires in two districts, including at an oil depot in Polevaya, Kursk Oblast. Smirnov wrote on Telegram that three storage tanks caught fire, requiring 82 firefighters and 32 units of equipment. Another two drones were reported shot down over the oblast by the defence ministry. Smirnov claimed that falling debris damaged residential buildings and injured one person. The fires were detected by NASA's FIRMS.
Sources: en.wikipedia.org
=== Design === A single-layer concrete paver has been utilized for the whole 15-metre width of the concrete slabs on either side of the road. The expressway will be designed to serve as a runway for airplanes to facilitate fast incident response in war-like situations, emergencies, or natural disasters. An Integrated Traffic Management System will be deployed along the expressway to keep tabs on vehicles speeding, lane discipline, or vehicular breakdowns. At every 40–50 km of interval on the e-way, wayside amenities like food plazas and rest areas along with electric charging stations for electric vehicles will be made available. Extensive landscaping, tunnel lighting, bridge beautification, improved street lighting, and digital signage will be used throughout the length of the expressway. Amongst the 32 major bridges that shall be built along the expressway, 5 bridges at Nagpur, Wardha, Nashik, Buldhana, and Thane are proposed to have a theme-based iconic design. To ensure digital readiness and resource availability, provisions will be laid down for optical fiber connectivity, natural gas pipelines, and electricity grid along the Mahamarg at industrial townships. With electric vehicle charging points proposed at prospecting locations along the expressway and solar plants planned to generate 250MW energy, the Samruddhi Corridor aims to become a model of an energy efficient corridor. Maximum locally available material, fly ash and plastic will be used to construct the expressway wherever possible.
An FSR is packed in a single trilaminate bag and contains filled pocket sandwiches, a pouch of tuna or chicken, two packets of ERGO high-energy drink mix, two high-energy First Strike Bars, a Soldier Fuel bar, two packets of beef jerky (BBQ or Teriyaki flavored), fortified applesauce, nut and fruit mix, caffeinated gum, and an accessory pack containing a beverage mix, salt, matches, tissues, plastic spoon, and cleansing moist towelettes. The FSR comes in three menus:
=== Moorosi's Revolt === The Cape government immediately began to undermine the traditional power structures of the Basuto. Under the terms of the Mercantile Law of 1871, trade was restricted to those in possession of a government license. In 1872, it implemented the responsible government system, under which the governor's legislative powers were transferred to the Cape Parliament. The Basuto were neither consulted nor formally informed. They were also barred from participating in the parliament unless they accepted to completely abandon their traditional laws and customs, a condition they deemed unacceptable. From that point on, Letsie I and the Governor's Agent in Basutoland, Colonel Griffith, became embroiled in a power struggle. The Cape-appointed magistrates were given autonomy in enforcing colonial legislation as they saw fit. The magistrates interfered with land disputes, when the Basuto previously held exclusive rights on land allocation. Authority over marriage disputes and disputes between the Basuto and white residents were likewise transferred to magistrates' courts. Basuto prophetesses claimed to have communicated in their dreams with the spirit of Moshoeshoe, who had become increasingly angry with the white man's interference in Basuto affairs. The southern corner of Basutoland was settled by the Baphuthi people. Their chief Moorosi was once a tributary ruler of Moshoeshoe who had reluctantly merged his territory with British Basutoland in 1869.
Shine–Dalgarno sequence In many prokaryotic messenger RNAs, the consensus sequence AGGAGGU, located 6–8 bases upstream of the translation start codon, which functions as a binding site for the ribosome by complementing a sequence in the ribosomal RNA.
Zverev maintained his top 5 ranking throughout the year. However, he still did not deliver any high-calibre results at the major tournaments. He was upset at the Australian Open by reigning Next Gen Finals champion and No. 59 Chung Hyeon in five sets in the third round. Zverev stated that issues at majors were "definitely not physical" when asked if his problems were physical or mental, and also attribute this lack of success to the extra pressure he was putting on himself at these events. Zverev did not reach his first final of the year until early April at the Miami Masters. Despite taking the first set of the final, he finished runner-up to American John Isner, who had never previously won a Masters title. Zverev continued his Masters success into the clay-court season, reaching the semifinals at the Monte Carlo Masters, winning his third career Masters title at the Madrid Open, and making the final at the Rome Masters. In Madrid, he defeated Dominic Thiem in the final to become the only active player outside of the Big Four to have won three Masters titles. He came close to winning back-to-back Masters events, going up a break in the third set against Nadal at the Italian Open. However, Nadal was able to recover and win the final five games of the match after a rain delay. Zverev had also defended his title at the Bavarian International Tennis Championships in his only other French Open tune-up to help build up a 13 match win streak that lasted until the Italian Open final.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.